Press Release

Printer Friendly Version View printer-friendly version
<< Back

Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018

10/25/18

WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter 2018 financial results on November 8, 2018, before the U.S. financial markets open. 

Histogenics will host a conference call on Thursday, November 8, 2018 at 8:30 a.m. ET.  To access the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “5491168” five to ten minutes before the start of the call.

A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com, or by clicking here.  A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the call.

About Histogenics Corporation

Histogenics (Nasdaq:  HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function.  Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis.  NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use.  NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care.  Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.  For more information on Histogenics and NeoCart, please visit www.histogenics.com.

Contact:

Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com

Histogenics logo

Source: Histogenics Corporation